Grifols’ Clayton site leads in plasma-derived therapies with $400M investment.

Grifols Therapeutics is redefining plasma-derived medicine manufacturing at its flagship Clayton campus. With a rich history that dates back to the 1990s and a transformative acquisition of Talecris in 2011, this site has evolved into a world-class facility producing therapies that treat chronic, rare, and life-threatening conditions.

Here are some key highlights:
🔹Robust Operational Legacy: Since acquiring Talecris for $3.4 billion, Grifols’ Clayton campus has grown to employ around 1,650 team members—and nearly 2,500 across North Carolina—cementing its role as a regional leader in plasma medicine manufacturing.
🔹State-of-the-Art Expansion: Recent investments include a $120 million purification and filling facility (now operational) and a $90 million fractionation plant that added 6 million liters of annual capacity, supporting a broader $400 million plasma-fractionation operation.
🔹Advanced Technologies: The facility leverages cutting-edge plasma fractionation, advanced chromatography systems, and state-of-the-art filling/finishing lines to produce vital therapies such as immunoglobulins, albumin, and clotting factors—all while adhering to rigorous regulatory and sustainability standards.

At PlantQuest, we’re proud to spotlight global leaders like Grifols who are pushing the boundaries of biopharmaceutical manufacturing to enhance patient care around the world.